Trichomonas vaginalis: tratamiento y resistencia a nitroimidazoles

https://doi.org/10.1016/S0213-005X(01)72580-3Get rights and content

First page preview

First page preview
Click to open first page preview

Bibliografía (204)

  • R.M. van der Weiden et al.

    Treatment failure in trichomoniasis and persistence of the parasites after Lactobacillus inmunotherapy; two case reports

    Eur J Obstet Gynecol Reprod Biol

    (1990)
  • F. Sorvillo et al.

    Trichomonas vaginalis and amplification of HIV- 1 transmission

    Lancet

    (1998)
  • R.E. Trussell

    Trichomonas vaginalis and trichomoniasis

    (1947)
  • K. Maeda et al.

    A new antibiotic, azomycin

    J Antibiot

    (1953)
  • C.D. Freeman et al.

    Metronidazole. A therapeutic review and update

    Drugs

    (1997)
  • C. Cosar et al.

    Activité de l’(hydroxy-2-éthyl)-1-méthyl-2-nitro-5-imidazole (8823 R.P.) vis-à-vis des infections expérimentales à trichomonas vaginalis

    Ann Inst Pasteur

    (1959)
  • P. Durel et al.

    Trial of an antitrichomonal derivate of imidazole (8823 R.P.) Comptes Rendus Soc Franç Gynécol

    (1959)
  • P. Durel et al.

    Systemic treatment of human trichomoniasis with a derivative of nitro-imidazole, 8823 R. P

    Br J Vener Dis

    (1960)
  • D.I. Edwards

    Nitroimidazole drugs-action and resistance mechanisms. I. Mechanisms of action

    J. Antimicrob Chemother

    (1993)
  • H.L. Howes et al.

    Tinidazole, a new antiprotozoal agent: Effect on Trichomonas and other protozoa

    Antimicrob Agents Chemother

    (1969)
  • J. Wallin et al.

    Tinidazole – a new preparation for Trichomonas vaginalis infections. II. Clinical evaluation of treatment with a single oral dose

    Br J Vener Dis

    (1974)
  • L. Hillström et al.

    Comparison of ornidazole and tinidazole in single- dose treatment of trichomoniasis in women

    Br J Vener Dis

    (1977)
  • R. Jones et al.

    An evaluation of tinidazole as single- dose therapy for the treatment of Trichomonas vaginalis

    Med J Aust

    (1977)
  • N. Kawamura

    Metronidazole and tinidazole in a single large dose for treating urogenital infections with Trichomonas vaginalis in man

    Br J Vener Dis

    (1978)
  • M.W. Miller et al.

    Tinidazole, a potent new antiprotozoal agent

    Antimicrob Agents Chemother

    (1970)
  • F. Vázquez Valdés

    Tricomoniasis (Ponencia)

  • D.H.H. Robertson et al.

    Treatment failure in Trichomonas vaginalis infections in females. I. Concentrations of metronidazole in plasma and vaginal content during normal and high dosage

    J Antimicrob Chemother

    (1988)
  • M. Sköld et al.

    Ornidazole: A new antiprotozoal compound for treatment of Trichomonas vaginalis infections

    Br J Vener Dis

    (1977)
  • J. Symonds

    Secnidazole- a nitroimidazole with a prolonged serum halflife

    J Antimicrob Chemother

    (1979)
  • A/ Notowicz et al.

    First experiences with single- dose treatment of vaginal trichomoniasis with carnidazole (R25831)

    Br J Vener Dis

    (1977)
  • A. Cantone et al.

    Nitroimidazole: A new systemic trichomonacide

    G Mal Infett Parassit

    (1969)
  • R.R. Willcox

    How suitable are available pharmaceuticals for the treatment of sexually transmited diseases? 1. Conditions presenting as genital discharges

    Br J Vener Dis

    (1977)
  • J.A. Uprcroft et al.

    Efficacy of new 5-nitroimidazoles against metronidazole-susceptible and–resistant Giardia, Trichomonas, and Entamoeba spp

    Antimicrob Agents Chemother

    (1999)
  • Boreham PFL, Smith NC, Shepherd RW. Drug resistance and the treatment of giardiasis. En: Wallis PM, Hammond BR (ed.)....
  • M. Müller

    Mode of action of metronidazole an anaerobic bacteria and protozoa

    Surgery

    (1983)
  • D.G. Lindmark et al.

    Hydrogenosomes in Trichomonas vaginalis

    J Parasitol

    (1975)
  • M. Müller

    The hydrogenosome

    J Gen Microbiol

    (1993)
  • E.M. Narcisi et al.

    In vitro effect of tinidazole and furazolidone on metronidazole- resistant Trichomonas vaginalis

    Antimicrob Agents Chemother

    (1996)
  • W.H.R. Lumsdem et al.

    Treatment failure in Trichomonas vaginalis vaginitis

    Genitourin Med

    (1988)
  • J.A. McFadzean et al.

    Further observations on strain sensitivity of Trichomonas vaginalis to metronidazole

    Br J Vener Dis

    (1969)
  • D.I. Edwards et al.

    Inactivation of metronidazole by aerobic organisms

    J Antimicrob Chemother

    (1979)
  • F. Wilmott et al.

    Zinc and recalcitrant trichomoniasis

    Lancet

    (1983)
  • A. Barbeau et al.

    Zinc, taurine and epilepsy

    Arch Neurol

    (1974)
  • G.D. Schott et al.

    Plasma zinc levels with anticonvulsant therapy

    Br J Clin Pharmacol

    (1978)
  • S.C. Robinson

    Trichomonal vaginitis resistant to metronidazole

    Can Med Assoc J

    (1962)
  • J.G. Meingassner et al.

    Strain of Trichomonas vaginalis resistant to metronidazole and other 5-nitroimidazoles

    Antimicrob Agents Chemother

    (1979)
  • J. Kulda et al.

    Metronidazole resistance of Trichomonas vaginalis as a cause of treatment failure in trichomoniasis

    Br J Vener Dis

    (1982)
  • M.S. Sprott et al.

    Trichomonal vaginitis refractory to treatment: Case report

    Genitourin Med

    (1988)
  • D.I. Edwards

    Nitroimidazole drugs- action and resistance mechanisms. II. Mechanisms of resistance

    J Antimicrob Chemother

    (1993)
  • K.A. Borchardt et al.

    An in vitro metronidazole susceptibility test for trichomoniasis using the InPouch TV test

    Genitourin Med

    (1996)
  • Cited by (12)

    • Flow cytometry evaluation of in vitro susceptibility of bovine isolates of Tritrichomonas foetus to metronidazole

      2019, Veterinary Parasitology
      Citation Excerpt :

      In our study, in addition to observing survival 48 h after treatment, we performed the subcultures of the trophozoites in Mz-free medium for 7 days in order to determine MLC. The values obtained indicate that all the bovine isolates studied are susceptible to Mz since resistance values were not observed in any of the conditions tested (extremely high concentrations) (Kulda et al., 1984; Vázquez et al., 2001). There are several methods to perform in vitro susceptibility tests that allow the rapid detection of new compounds with activity anti-T.

    • Antichagasic and trichomonacidal activity of 1-substituted 2-benzyl-5-nitroindazolin-3-ones and 3-alkoxy-2-benzyl-5-nitro-2H-indazoles

      2016, European Journal of Medicinal Chemistry
      Citation Excerpt :

      However, there are no effective alternatives for patients who develop side effects or hypersensitivity, or when its use is contraindicated. Moreover, it is estimated that approximately 5–10% of diagnosed cases of trichomonosis are caused by nitroimidazoles-resistant isolates [42,43]. Therefore, the search for alternative drugs for the treatment of both parasitic pathologies is urgently needed.

    • Synthesis and in vitro and in vivo biological evaluation of substituted nitroquinoxalin-2-ones and 2,3-diones as novel trichomonacidal agents

      2015, European Journal of Medicinal Chemistry
      Citation Excerpt :

      Metronidazole and tinidazole (5-nitroimidazole derivatives) are the only drugs approved by the U.S. Food and Drug Administration (FDA) for the treatment of trichomonosis [12] since the early 60s. Metronidazole presents a good pharmacokinetic profile [13] and high percentage of cure rates have been reported [14]; however, the development of resistance cases [15] and iatrogenic side effects [16] make necessary the search for novel chemical candidates to increase the therapeutic arsenal. On the other hand, quinoxaline derivatives are interesting molecules with diverse pharmacological properties.

    View all citing articles on Scopus
    View full text